Literature DB >> 17599176

Alleviation of hot flashes with increase in venlafaxine dose.

Prasad R Padala, Srinivas B Rapuri, Kalpana P Padala.   

Abstract

Entities:  

Year:  2007        PMID： 17599176      PMCID： PMC1894834          DOI： 10.4088/pcc.v09n0114c

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN： 1523-5998


× No keyword cloud information.
  6 in total

1.  Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression.

Authors:  Charlotte O Ladd; D Jeffrey Newport; Kimberly A Ragan; Ada Loughhead; Zachary N Stowe
Journal:  Depress Anxiety       Date:  2005       Impact factor: 6.505

2.  Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial.

Authors:  C L Loprinzi; J W Kugler; J A Sloan; J A Mailliard; B I LaVasseur; D L Barton; P J Novotny; S R Dakhil; K Rodger; T A Rummans; B J Christensen
Journal:  Lancet       Date:  2000-12-16       Impact factor: 79.321

3.  Differential physiological effects of a low dose and high doses of venlafaxine in major depression.

Authors:  Guy Debonnel; Elise Saint-André; Chantal Hébert; Claude de Montigny; Normand Lavoie; Pierre Blier
Journal:  Int J Neuropsychopharmacol       Date:  2006-05-11       Impact factor: 5.176

Review 4.  Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis.

Authors:  Heidi D Nelson; Kimberly K Vesco; Elizabeth Haney; Rongwei Fu; Anne Nedrow; Jill Miller; Christina Nicolaidis; Miranda Walker; Linda Humphrey
Journal:  JAMA       Date:  2006-05-03       Impact factor: 56.272

5.  Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial.

Authors:  Michele L Evans; Elizabeth Pritts; Eric Vittinghoff; Karen McClish; Kevin S Morgan; Robert B Jaffe
Journal:  Obstet Gynecol       Date:  2005-01       Impact factor: 7.661

6.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.